News

Eli Lilly: Competition Melts Away
Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...
Should You Invest in This Under-the-Radar Weight Loss Stock?
Rhythm Pharmaceuticals' lone approved product currently generates minimal sales. If you're interested in capitalizing on the ...
2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
Zacks Investment Research on MSN4d
Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?
Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...
These 2 Stocks Could More Than Double Your Money, According to Wall Street. Is It Time to Buy?
Key Points Analyst expectations are far above the prices you'd need to pay now to own a couple of biotechnology stocks.Compass Pathways is developing psilocybin as a treatment for depression.Viking ...
Investing Snacks6d
Eli Lilly’s Bold Step in Obesity Drug Research
Eli Lilly is advancing its Phase 2 clinical trial to test LY3841136 for weight management in obese and overweight adults.
Here's How to Play AbbVie Stock as it Reaches Golden Cross
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Endometrial Cancer Clinical Trial Pipeline Insights: 50+ Companies Shaping Future Treatment Paradigms Delveinsight
Endometrial Cancer is a type of cancer that begins in the lining of the uterus, most commonly affecting postmenopausal women. Rising prevalence due t ...
Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly's Zepbound
An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...